Objective: Some systemic inflammatory response-based biomarkers are promising for predicting prognosis of non-muscle-invasive bladder cancer (NMIBC) patients and can contribute to the risk classification without any significant cost. We aimed to evaluate the neutrophil-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) for the prediction of recurrence and progression risk in patients with NMIBC. Material and Methods: The study included a retrospective analysis of 211 patients who underwent transurethral resection of bladder (TURB) in a tertiary referral center between 2015 and 2019. The receiver operating characteristic (ROC) curve was used to determine the cut-off value. The Kaplan-Meier curves and the log-rank test were constructed to evaluate the recurrence-free and progression-free survival rates according to different levels of inflammatory markers. The multivariate regression analysis was undertaken to estimate the independent prognostic factors. Results: The optimal cut-off value of SII was found to be 568 in the ROC analysis. According to the multivariate analysis, the SII value, number of tumors at the time of initial TURB, and European Organization for Research and Treatment of Cancer (EORTC) recurrence classification were statistically significant parameters in predicting recurrence. While tumor size, NLR, and SII achieved statistically significant levels in the univariate analysis, they didn’t have significance in the multivariate analysis. Conclusion: The SII, number of tumors, and EORTC recurrence classification are prognostic parameters that can be used in the assessment of recurrence. However, inflammatory parameters do not have the same predictive ability in the prediction of the progression rate.
Objective: Positive surgical margins remain clinically relevant after robot-assisted radical prostatectomy (RARP). Whether performing extended pelvic lymph node dissection (ePLND) before, rather than after, prostatectomy is associated with lower apical positive surgical margin (PSM) rates has not been evaluated with adjusted comparative data.Materials and Methods: We performed a retrospective cohort study of 250 consecutive patients who underwent primary RARP with ePLND at a single tertiary centre. Patients were classified by operative sequence as ePLND-first (n = 121) or prostatectomy-first (n = 129). The primary multivariable analyses were conducted in the full 250-patient cohort with nerve-sparing intent coded as a 3-level categorical variable; a pre-specified subgroup analysis was conducted in the 188 patients undergoing any form of nerve-sparing surgery. The primary endpoint was apical PSM. Because apical PSM events were sparse, the adjusted analysis used Firth penalised logistic regression.Results: Baseline characteristics were similar between groups. Apical PSM occurred in 6 of 121 patients (5.0%; 95% confidence interval [CI] 2.3% to 10.4%) in the ePLND-first group and 13 of 129 (10.1%; 95% CI 6.0% to 16.5%) in the prostatectomy-first group. In the primary multivariable analysis of the full 250-patient cohort, ePLND-first sequencing was associated with lower adjusted odds of apical PSM (adjusted OR 0.38; 95% CI 0.14 to 1.03; p = 0.056); in the pre-specified nerve-sparing subgroup (n = 188), the adjusted association was stronger (OR 0.19; 95% CI 0.04 to 0.97; p = 0.046; unadjusted 1.2% vs 8.8%, Fisher’s exact p = 0.023). Total operative time was shorter in the ePLND-first group (195.2 vs 202.9 min; p = 0.029). Lymph node yield and major complication rates were similar between groups.Conclusion: In this retrospective cohort, performing ePLND before prostatectomy was associated with directionally lower adjusted odds of apical PSM during RARP in the full 250-patient cohort, with a stronger association in the pre-specified nerve-sparing subgroup analysis. For men undergoing nerve-sparing RARP with planned ePLND, sequence may represent a practical operative strategy associated with lower apical margin risk without an evident perioperative penalty.